Archive · 14 Aug 2025
Analyst Advises Avoiding Pharma Stocks Amid US-India Uncertainty
An expert suggests staying away from investing in pharmaceutical stocks because of the uncertain relationship between India and the United States.
The expert believes that current prices may seem attractive, but the situation is too unpredictable to invest right now.
The US government is also working on storing important drug ingredients to ensure a supply.
This involves a list of essential drugs and a plan to store enough ingredients for six months.
Analyst Mitesh Panchal advises against investing in pharma stocks.
Tensions between India and the US are cited as a primary concern.
Panchal recommends avoiding pharma stocks across all market capitalizations.
The US President signed an order to stock the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).
The ASPR will secure a six-month supply of APIs for 26 critical drugs.
- Who
- Mitesh Panchal, a SEBI-registered analyst.
- What
- Analyst Mitesh Panchal advises against investing in pharma stocks.
- When
- The advice was given on Thursday.
- Where
- N/A
- Why
- Due to uncertainty between India and the US regarding the pharma sector.
Investors
Possible Investors
Investment Strategy
Investors
Avoid pharma stocks until stability.
Possible Investors
Potentially invest, monitor situation.
- Analyst
- Mitesh Panchal
- Recommendation
- Avoid pharma stocks
- Reason
- Tensions between India and the US
- US Action
- Stocking SAPIR with APIs
- SAPIR Goal
- 6-month supply of APIs for critical drugs